In HFD group, the beneficial effects of elafibranor with respect to hepatic steatosis, whole body fat mass, and GTT were counteracted by EX527 (a specific SIRT1 inhibitor), but not in body weight changes (Figures 1(b)–1(d) and 2(e), Table 2)., This evidence concerns the gene SIRT1 and Hepatic steatosis.